KRAS and non-small cell lung carcinoma: Clinically, it has demonstrated cerebrospinal fluid penetration and BM regression in preliminary findings from the phase 1b portion of the KRYSTAL-1 trial; a retrospective database analysis was initially performed to better understand the clinicopathological features of KRAS G12C-mutant NSCLC patients with BM (56).